GMAB vs. MTD: Genmab vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do Genmab (GMAB) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Genmab (GMAB) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Mettler-Toledo (MTD) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Genmab (GMAB) and Mettler-Toledo (MTD)
Profile Item	GMAB	MTD
Name	Genmab A/S American Depositary Shares	Mettler-Toledo International Inc.
Country/Region	Denmark	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	32.98 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	June 1, 2009	November 14, 1997
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

GMAB

MTD

GSPC

Genmab (GMAB) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Genmab (GMAB) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Genmab (GMAB) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
Total Return (1Y)	91.17%	21.58%
Total Return (3Y, Annualized)	20.70%	19.54%
Total Return (5Y, Annualized)	3.98%	2.36%

Risk Profile

Drawdown History

GMAB

MTD

GSPC

Genmab (GMAB) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Genmab (GMAB) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
Volatility (1Y, Annualized)	45.68%	31.70%
Beta (5Y)	0.72	1.15
Max Drawdown (5Y)	-61.79%	-43.47%
Avg. Volume (3M)	4.09M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

GMAB and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
Sharpe Ratio (1Y)	1.90	0.55
Sortino Ratio (1Y)	3.82	0.75

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Genmab (GMAB) earns 12.07% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max: 109.18%
GMAB: 12.07%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

Genmab (GMAB) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; GMAB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Mettler-Toledo (MTD) at 22.25% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max: 18.05%
GMAB: 16.97%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Genmab (GMAB) at 37.15% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max: 83.12%
GMAB: 37.15%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
ROE (TTM)	12.07%	--
ROA (TTM)	8.24%	20.09%
Net Margin (TTM)	16.97%	22.25%
Operating Margin (TTM)	37.15%	28.70%
Gross Margin (TTM)	92.67%	59.16%

Growth

Revenue Growth

Both Genmab (GMAB) at 19.19% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Genmab (GMAB) at -9.23% and Mettler-Toledo (MTD) at 3.88% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
Revenue Growth (YoY)	19.19%	3.98%
Revenue Growth (3Y CAGR)	21.23%	0.90%
EPS Growth (YoY)	-9.23%	3.88%
EPS Growth (3Y CAGR)	8.48%	3.06%

Financial Strength

Current Ratio (MRQ)

Both Genmab (GMAB) at 2.45 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
GMAB: 2.45
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but MTD is more stretched: Genmab (GMAB) at 0.82 sits in the higher-leverage quartile and Mettler-Toledo (MTD) at 26.06 is above its industry benchmark range.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max: 1.42
GMAB: 0.82
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
Current Ratio (MRQ)	2.45	1.10
Debt / Equity (MRQ)	0.82	26.06
Net Debt / EBITDA	2.45	1.58

Dividends

Dividend Yield (TTM)

Neither Genmab (GMAB) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Genmab (GMAB) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Mettler-Toledo (MTD) at 37.38 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max: 85.34
GMAB: 45.84
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Genmab (GMAB) at 7.68 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max: 58.18
Q3: 25.77
GMAB: 7.68
Median: 7.30
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Genmab (GMAB) at 5.36 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max: 13.53
Q3: 6.54
GMAB: 5.36
Median: 3.25
Q1: 1.69
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Genmab (GMAB) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Genmab (GMAB) and Mettler-Toledo (MTD)
Metric	GMAB	MTD
P/E Ratio (TTM)	45.84	37.38
P/S Ratio (TTM)	7.68	8.16
P/B Ratio (MRQ)	5.36	442.71
Free Cash Flow Yield (TTM)	2.59%	1.97%